← Oncology Approval Tracker

FDA DECISION ·

Pemetrexed Injection (Actavis) + cisplatin

pemetrexed plus cisplatin · Actavis

FDA approvalNew or expanded indicationMalignant pleural mesothelioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Initial therapy with cisplatin for malignant pleural mesothelioma that is unresectable or unsuitable for curative surgery, using the specified pemetrexed product.

LAMPGEN ANALYSIS

Why it matters

The supplement adds a distinct pleural mesothelioma indication to this product's label.

What research teams should watch

Document diagnosis and surgical candidacy and check product-level preparation instructions.

PRIMARY RECORDS

Sources